Skip to content

Author

H. Bundgaard

We have 8 of 735 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

A randomized controlled trial of a novel AI-based prognostic decision support tool integrated into the electronic health record for ischemic heart disease: Rationale and design of the PM Heart trial.

BACKGROUND Ischemic heart disease (IHD) is the leading global cause of years of life lost. Although the clinical presentation and progression of IHD differ widely, clinical management is relatively uniform. To improve risk stratification and clinical management, we developed a decision support tool - the PMHeartIHD Alg...

A. Ringgaard, S. Rand, Chao-Qun Zheng et al. · 0 citations
Nov 2026

Abstract 4980: Interplay Between Body Mass Index and Patient-Reported Health Status in Early-Stage Hypertrophic Cardiomyopathy

Background: Symptoms and functional impairments have historically represented the primary targets of hypertrophic cardiomyopathy (HCM) management. Obesity has been shown to be associated with worse symptoms and clinical outcomes in HCM, but the extent to which obesity influences patient-reported health status across...

J. Ostrominski, B. Claggett, A. Axelsson Raja et al. · 0 citations
Open access Oct 2026

Alzheimer's disease genetics converges on microglial and neuronal dysregulation.

Alzheimer's disease (AD) is the most common cause of dementia, with global case numbers projected to reach 153 million in 20501. AD is highly heritable, with twin-based heritability estimates of 60-80%2. Although 1,200 causal loci are predicted to exist for AD3, approximately 80 loci have been associated with AD in two...

E. Uffelmann, D. Wightman, S. Bahrami et al. · 0 citations
Review Open access Sep 2026

[Clinical pharmacogenetics and the use of biobanks].

The Danish strategy for personalised medicine 2025-2027 includes initiatives for improving the use of pharmacogenetic information to guide drug therapy, and this review emphasises the need for improved infrastructure and data access for physicians.

M. Bentsen, J. Bundgaard, N. Brøns et al. · 0 citations
Open access Sep 2026

The Half-Life of Long Forms of Cardiac Troponin T.

BACKGROUND Long forms of cardiac troponin T (cTnT) are promising markers that may differentiate myocardial infarction from other causes of acute and chronic myocardial injury. However, to understand the clinical utility of long cTnT, knowledge of the half-life (T½) is key. By using auto-transfusion in humans we determi...

R. Hasselbalch, S. Salonen, J. Kristensen et al. · 0 citations
Open access Aug 2026

Genetic architecture of cytokine autoantibodies and associated risk of common diseases

Genetic predisposition to IL-1α autoantibodies is associated with reduced risk of rheumatoid arthritis and certain cancers, whereas genetic predisposition to IL-6 autoantibodies is associated with increased risk of diabetes, mirroring prior clinical observations.

J. V. von Stemann, Joseph Dowsett, R. Teglgaard et al. · 0 citations
Open access Sep 2026

Optimizing Screening Intervals for At-Risk Relatives of Dilated Cardiomyopathy Carrying a TTNtv.

BACKGROUND Cardiomyopathy guidelines recommend routine screening of at-risk relatives with dilated cardiomyopathy (DCM). Titin-truncating variants are the most prevalent cause. However, the diagnostic yield of screening is low. Risk-based stratification could optimize screening intervals and resource allocation. This s...

S. Muller, N. Beelen, A. Paldino et al. · 0 citations
Aug 2026

Prevalence of Silent Atherosclerosis across Adult Life.

This study of silent atherosclerosis showed that the disease was detectable in early adulthood, with age- and sex-associated increases in prevalence across arterial territories and marked increases in plaque volume.

H. Bundgaard, I. García-Lunar, K. F. Kofoed et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.